west virginia semaglutide gastric stasis law firm in Gastrointestinal Motility Effects of GLP-1 Receptor Agonists West Virginia ends GLP-1 subsidy

This transformation comes at a crucial time as the obesity treatment landscape undergoes rapid evolution with analysts projecting the GLP-1 market to exceed $100 billion by 2030.1 AI is fundamentally changing how we conduct and optimize clinical trials for GLP-1 therapies

Obesity and asthma: implications for treatment

This is particularly helpful for needle-anxious beginners who need to build confidence

Read articleListen Press Release New Survey Shows Strong Patient Support for Personalized Obesity Interventions PR Newswire - - August 1, 2024 - Respondents ages 18 to 65 highlight urgency for medical recognition, scientifically proven interventions, and genetic testing for personalized obesity treatment

10.1056/NEJMoa1916038 N Engl J Med

One study found that although semaglutide does not increase the risk of diabetic retinopathy, older people aged 60 and over who have had diabetes for 10 years or more may have an increased risk of diabetic retinopathy when using semaglutide (Ozempic)